MYT1L restricted glioblastoma cell switching and suppressed tumour growth in preclinical models

MYT1L, a regulator that switches off gene activity, restricted glioblastoma cells' ability to change state and suppressed tumour growth and invasion in preclinical models. The growth and invasion findings came from experiments in living models, not patients. MYT1L also restricted cell switching under standard-of-care therapy, the usual recommended treatment. Combining computer predictions with experiments in patient-derived models, researchers found that switching followed a structured, predictable program. Their analysis covered profiles of more than one million cells from primary glioblastomas. MYT1L was the dominant regulator keeping cells in a neuronal-like state, resembling nerve cells.
The researchers investigated whether glioblastoma cells switched state randomly or followed predictable controls on gene activity. Glioblastoma resists therapy despite genetic stability during treatment, suggesting that cellular plasticity, the ability to change state without genetic changes, is a central driver of progression.
The team analysed measurements of several molecular layers within individual cell nuclei using scDORI, short for single-cell deep multi-omic regulatory inference. This computer tool learns patterns in those measurements to infer networks controlling gene activity, including the role of enhancers, regions of DNA that regulate that activity. Researchers tested its predictions by systematically disrupting parts of the networks in patient-derived models.
The routes between cell states followed a predictable hierarchy. Cells could also cross between lineages, groups of cells with related developmental identities, in ways absent from normal nervous-system development. States with little switching, such as the neuronal-like state, were actively maintained rather than settled end points. A network of repressors, regulators that switch off gene activity, kept alternative identities suppressed.
MYT1L was the dominant member of that network. It bound to and suppressed the main regulators of every alternative state, maintaining the neuronal-like identity. Experiments involving loss of MYT1L reactivated switching and accelerated malignant features. The results indicated that keeping cells in a state with little switching required continued suppression of alternative identities.
The findings led the authors to nominate these safeguard repressors as candidate therapeutic targets. Their role differs from that of activators, which push cells towards a specialised identity: the repressors continually silence alternatives. The authors suggested potential relevance to other cancers in which switching between cell states drives resistance to therapy.
Written by the Genomes desk from the primary source cited and linked above and checked against it. Research use only; not medical advice. Corrections: [email protected].